On March 20, 2025 Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, reported the presentation of the discovery of a novel mechanism for BRD9 degradation, differentiated from cereblon- or VHL-based PROTACs using the Company’s novel Targeted Glue technology (Press release, Amphista Therapeutics, MAR 20, 2025, View Source [SID1234651318]). These will be at the 2nd SMR Molecular Glues meeting being held on 21 March in Stevenage, UK, and the 5th Annual TPD and Induced Proximity Summit Europe being held 25-27 March in London, UK.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Marta Carrara, Associate Director Target Discovery & Validation at Amphista, will deliver the oral presentations that describe the generation of selective and potent degraders of BRD9, an emerging target in acute myeloid leukemia. Amphista’s proprietary Targeted Glue catalyzes degradation via DCAF16, a relatively uncharacterised E3 ligase, and therefore has the potential to create novel TPD therapeutics for application across a wide range of indications.
These data illustrate the strength of the Company’s proprietary chemistry and its Eclipsys platform in enabling the rational design of orally bioavailable protein degraders.
Details of presentations:
Conference: 2nd SMR Molecular Glues meeting, Stevenage, UK
Presentation Date and Time: Friday 21st March, 11.50am-12.30pm GMT
Presentation Title: Degradation of BRD9 by a novel "Targeted Glue"
Conference: 5th Annual TPD and Induced Proximity Summit Europe, London, UK
Presentation Date and Time: Wednesday 26th March, 9.00am GMT
Presentation Title: Rational design of a novel DCAF16-recruting BRD9 Targeted Glue